SCHEDULE 13G: Suvretta Capital and Affiliates Disclose Significant Passive Stake in DBV Technologies S.A.

Suvretta Capital Management, LLC, Aaron Cowen, and Averill Master Fund, Ltd. have jointly disclosed a passive beneficial ownership of up to 9.9% in DBV Technologies S.A., primarily through ordinary shares and pre-funded warrants.

Summary

• Suvretta Capital Management, LLC, Aaron Cowen, and Averill Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership in DBV Technologies S.A. (the "Issuer").
• Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 15,176,015 Ordinary Shares, representing 9.9% of the class.
• Averill Master Fund, Ltd. beneficially owns 13,385,351 Ordinary Shares, representing 8.81% of the class.
• These holdings include both currently held Ordinary Shares and Ordinary Shares issuable upon the exercise of certain pre-funded warrants.
• A "Beneficial Ownership Limitation" is in place, preventing the exercise of warrants if it would result in the holder, together with its affiliates, beneficially owning in excess of 9.99% of the Issuer's outstanding shares.
• Without giving effect to this limitation, Suvretta Capital and Aaron Cowen would beneficially own 56,822,964 Ordinary Shares, and Averill Master Fund, Ltd. would beneficially own 50,177,963 Ordinary Shares.
• The percentage of class is calculated based on 151,912,061 Ordinary Shares outstanding, which comprises 136,946,267 Ordinary Shares outstanding as of March 27, 2025, plus 14,965,794 Ordinary Shares issuable upon exercise of the warrants after giving effect to the Beneficial Ownership Limitation.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by a reputable firm, which can be seen as a positive signal of confidence in the company. The structure with pre-funded warrants and a blocker is standard for such investments. There are no negative operational or financial disclosures from the company itself within this document.

Positives

• The disclosure of a significant passive investment by Suvretta Capital Management, a reputable investment firm, and its affiliates, may signal confidence in DBV Technologies S.A.'s long-term prospects.
• The investment structure, utilizing pre-funded warrants, provides flexibility for the investors while adhering to beneficial ownership limitations, which can be a strategic approach to large-scale investments.

Negatives

• The explicit 9.99% beneficial ownership limitation on warrant exercise caps the immediate voting power and influence of these significant investors, potentially limiting their ability to drive rapid corporate changes.

Risks

• The "Beneficial Ownership Limitation" on the exercise of warrants means that the full potential ownership and associated voting power of the Reporting Persons are currently restricted, which could impact their influence on corporate decisions or strategic direction.
• The value of the pre-funded warrants, and thus the overall investment, is inherently tied to the future performance and share price of DBV Technologies S.A.'s Ordinary Shares.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance provided by DBV Technologies S.A. itself. It reflects the current investment position and intent of the reporting entities.

Management Comments

• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired or held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant passive investment by a prominent investment firm in a biotechnology company. Such investments are common in the biotech sector, where companies often rely on external funding and institutional support for research, development, and commercialization efforts. The passive nature of this investment (indicated by a Schedule 13G filing) suggests the investor is not seeking to actively influence management or strategy, which can be viewed positively as it implies confidence without immediate disruptive intent. DBV Technologies S.A. is a French company, and the filing relates to its Ordinary Shares, which are likely traded as American Depositary Shares (ADS) in the U.S., highlighting the global nature of biotech funding.

Comparison to Industry Standards

• The 9.9% beneficial ownership stake by Suvretta Capital and Aaron Cowen represents a substantial passive position, often interpreted as a strong vote of confidence from a specialized healthcare investor.
• The use of pre-funded warrants combined with a beneficial ownership blocker (9.99%) is a standard mechanism in biotech financing. This structure allows investors to gain significant exposure to a company's equity while avoiding triggering certain regulatory thresholds (e.g., 10% ownership that might require a Schedule 13D filing or other reporting obligations) or anti-takeover provisions.
• The investment in a French company (DBV Technologies S.A.) by U.S.-based entities underscores the cross-border nature of capital flows and investment opportunities within the global biotechnology industry.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive indicator of confidence in DBV Technologies S.A., potentially leading to increased investor interest and stability.
• Company Management: The passive nature of the investment suggests no immediate pressure for strategic or operational changes from these specific investors, allowing management to focus on existing plans.

Next Steps

• DBV Technologies S.A. will continue its operations and strategic initiatives.
• The Reporting Persons will continue to hold their investment, subject to their investment strategy and market conditions.
• Future Schedule 13G or 13D filings would be required if the beneficial ownership percentage significantly changes (e.g., crosses a 1% threshold) or if the investment intent shifts from passive to active.

Key Dates

Recommendation

Keywords

DBV Technologies S.A., Schedule 13G, Beneficial Ownership, Suvretta Capital Management, Aaron Cowen, Averill Master Fund, Pre-funded Warrants, Biotechnology, SEC Filing, Institutional Investor, Passive Investment, Ordinary Shares